Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

QGEN - Qiagen N.V. Последние новости | Finranks

Home

/

QGEN

Q

Qiagen N.V. (QGEN)

NYQ – Цена в реальном времени. Валюта: USD

39.41

+0.47 (1.21%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

39.42

+0.01 (0.03%)

После закрытия: Jun 26, 2026, 5:52 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Qiagen N.V. (QGEN) Discusses Digital PCR Technology and Applications in Environmental Sample Analysis Transcript

Qiagen N.V. (QGEN) Discusses Digital PCR Technology and Applications in Environmental Sample Analysis Transcript

Qiagen N.V. (QGEN) Discusses Digital PCR Technology and Applications in Environmental Sample Analysis Transcript

QIAGEN Expands QIAcuity Gene Expression Portfolio to Drive dPCR Use

QIAGEN Expands QIAcuity Gene Expression Portfolio to Drive dPCR Use

QGEN's QIAcuity expansion adds gene expression assays, multiplexing, automation and analysis tools to drive dPCR adoption.

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across life sciences and biopharma applications. As researchers increasingly seek higher sensitivity, greater precision and improved multiplexing capabi.

Qiagen (QGEN) Up 12.1% Since Last Earnings Report: Can It Continue?

Qiagen (QGEN) Up 12.1% Since Last Earnings Report: Can It Continue?

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN).

Qiagen N.V. (QGEN) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Qiagen N.V. (QGEN) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Qiagen N.V. (QGEN) Presents at Jefferies Global Healthcare Conference 2026 Transcript

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE: QGEN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Видео

No Data

There is no data to display

Пресс-релизы

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across life sciences and biopharma applications. As researchers increasingly seek higher sensitivity, greater precision and improved multiplexing capabi.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN).

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE: QGEN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

VENLO, Netherlands, & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts related to the Bundibugyo ebolavirus outbreak. The assays are designed for use with the QIAcuity digital PCR system and are intended to help qualified laboratories evaluate emerging pathogen targets in research, wastewater s.